The disposition of cyclophosphamide in a group of myeloma patients.
The disposition of cyclophosphamide and its alkylating metabolites was investigated in a group of myeloma patients with varying degrees of renal function impairment. No correlation between renal function and clearance of cyclophosphamide or its alkylating metabolites was found. No evidence of accumulation of cyclophosphamide or alkylating activity was found in four patients receiving radiolabelled cyclophosphamide. Renal function was found to be related to the reciprocal of the area under curve of alkylating activity, indicating that this area increased as renal function decreased. In view of the large nonrenal component of alkylating activity elimination and the large inter-subject variability, it is recommended that dose of cyclophosphamide is not altered in moderate impairment of renal function.
D000477:Alkylating Agents; D001835:Body Weight; D003520:Cyclophosphamide / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism*
D000477:Alkylating Agents; D003520:Cyclophosphamide